Michael Beyeler
4 Papers
13 Citations
Michael Beyeler is an academic researcher. The author has contributed to research in topics: Surrogate endpoint & Clinical endpoint. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Rolf A. Stahel,Oliver Riesterer,A. Xyrafas,Isabelle Opitz,Michael Beyeler,Adrian F. Ochsenbein,Martin Früh,Richard Cathomas,Kristiaan Nackaerts,Solange Peters,Christoph Mamot,Alfred Zippelius,Carlo Mordasini,Clemens B. Caspar,K. Eckhardt,Ralph A. Schmid,Daniel M. Aebersold,O. Gautschi,Wolfgang Nagel,Michael Töpfer,Jerome Krayenbuehl,Karin Ribi,llja F Ciernik,Walter Weder +23 more
TL;DR: The findings do not support the routine use of hemithoracic radiotherapy for malignant pleural mesothelioma after neoadjuvant chemotherapy and extrapleural pneumonectomy.
195
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Arnoud J. Templeton,Karin Ribi,Christian Surber,H. Sun,Shu-Fang Hsu Schmitz,Michael Beyeler,Daniel Dietrich,Markus Borner,Annette Winkler,A. Müller,Lukas von Rohr,Ralph Winterhalder,Christoph Rochlitz,Roger von Moos,Khalil Zaman,Beat Thürlimann,Thomas Ruhstaller +16 more
TL;DR: Using topical aluminum chlorohydrate as an antiperspirant appears to reduce the incidence of grade 2 or 3 palmar-plantar erythrodysesthesia following pegylated liposomal doxorubicin chemotherapy for metastatic breast cancer.
24
Lba37_prneoadjuvant chemotherapy and extrapleural pneumonectomy (epp) of malignant pleural mesothelioma (mpm) with or without hemithoracic radiotherapy: final results of the randomized multicenter phase ii trial sakk17/04
Rolf A. Stahel,Oliver Riesterer,X Alexandros,Isabelle Opitz,Michael Beyeler,Adrian F. Ochsenbein,Martin Früh,Richard Cathomas,Kristiaan Nackaerts,Solange Peters,Christoph Mamot,Alfred Zippelius,C Mordasini,K Clemens,K. Eckhardt,Ralph A. Schmid,W Nagel,Daniel M. Aebersold,O. Gautschi,Walter Weder +19 more
TL;DR: This study did not reach the primary endpoint which was defined as one-year increase in loco-regional relapse-free survival and thus does not support the routine use of hemithoracic RT after neoadjuvant chemotherapy and EPP.
11
Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase lll trial (SAKK 92/08).
Thomas Ruhstaller,Karin Ribi,H. Sun,Shu-Fang Hsu Schmitz,Markus Borner,Annette Winkler,Andreas Mueller,Lukas von Rohr,Ralph Winterhalder,Christoph Rochlitz,Roger von Moos,Sandro Anchisi,Clemens B. Caspar,Khalil Zaman,Alexandre Bodmer,Michael Beyeler,Simona Berardi,Beat Thürlimann,Arnoud J. Templeton +18 more
TL;DR: It is postulated that prophylactic administration of an antiperspirant (F511 cream) prior and during treatment with PLD could decrease the incidence of PPE.
6